Cardiology

A pilot study presented at ACC.22 demonstrates the impact of implementation of an RPM program to improve blood pressure control in patients with hypertension at primary care clinics.

New research suggests a consistent risk reduction of empagliflozin may be theorized independent of region or race categories.

An investigator discusses new ACC 2022 data showing valvular heart disease is disparately impacting older patients, as well as females, with previously unanticipated manifestations.

Hospitalized HFrEF patients had a higher rate of the cardiovascular death or a worsening heart failure event than outpatients

Guideline writing committee co-chair Biykem Bozkurt, MD, PhD, discusses the utility of the drug class in HF prevention and risk reduction.

On March 30, Akieba Therapeutics announced the receipt of a CRL from the FDA for their NDA for vadadustat as a treatment for anemia due to chronic kidney dialysis in adult patients on dialysis and not on dialysis.

Headed to ACC.22 this weekend or following along virtually? Hear from Don't Miss a Beat co-hosts Drs. Vaduganathan and Greene on their top picks from the late-breaking sessions at the upcoming American College of Cardiology meeting.

A systematic review from ACC.22 suggests wearable technology, specifically those for assessing heart rate and arrhythmias, may be less accurate when used by individuals with darker skin tones.

Dr. Bailey highlights the innovative nature of the procedure and breaks down the process at his institution.

In a population aged 70 years and older, a remote history of VT was associated with an increased risk of VT independent of other factors.

With the newest indication, the GLP-1 agonist is now available in 3 different doses for diabetic adults.

Lead investigator of a recent study assessing risk of long-term COVID-19 risk using data from more than 11 million patients, Ziyad Al-Aly, MD, sits down with Practical Cardiology for a Q&A on the findings from his research.

Large variations were observed in the transition between monotherapy and dual combination therapy for hypertension across countries and demographic group.

An analysis of data from more than 110k hospitalized patients with COVID-19 suggests aspirin use on the first day of hospitalization was linked to lower odds for both in-hospital mortality and pulmonary embolism in weighted analyses.

Strategies to improve enrollment of underrepresented populations were centered on study design and site selection, community engagement, and changing the research paradigm.

Greater increases were observed among members of racial and ethnic minority groups, with the highest increase among non-Hispanic Black individuals.

Data from the REMAP-CAP trial suggests use of aspirin or P2Y12 inhibitors had a low likelihood of improving organ support-free days in critically ill patients with COVID-19 within 21 days compared to no antiplatelet therapy.

A favorable lifestyle is associated with a lower risk of coronary artery disease in carriers and noncarriers of FH variants.

Dr. Bajona highlights the patient risks of HCM, new advances in treatment options, and the importance of screening efforts.

Children exposed and not exposed to neonatal hypoglycemia did not have significant differences in rates of low educational performance at 9 to 10 years old.

For patients treated with DOACs, the investigators suggest temporarily interrupting treatment rather than continued use.

Data from a within-trial cost-effectiveness evaluation of data from the Salt Substitute and Stroke Study suggest use of the 75% sodium chloride 25% potassium chloride salt substitute had a 95% probability of being cost-saving and a greater than 99.9% probability of being cost-effective.

Investigators in Israel perform the largest retrospective review of patients with rheumatic fever in a developed country, spanning 25 years of research.

Data from the COSMOS trial demonstrate use of a cocoa flavanol supplement in older adults could cut the risk of cardiovascular death by more than 25%.

Dr. Lee highlights the process of identifying CTEPH and the patient population, as well as the available treatments for the condition.

Apixaban prescription beyond 90 days showed no difference in hospitalization risk for major bleeding.

The phase 3 trial was stopped following a formal interim assessment that met pre specified criteria for positive efficacy in patients with chronic kidney disease.

Data show the absolute risk reductions of treatment with statins in terms of all-cause mortality, myocardial infarction, and stroke are modest compared with the relative risk reductions.

Data from an ongoing, prospective study conducted in multiple countries provides an overview of characteristics and outcomes among patients with type 2 myocardial infarction.